Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
Authors
Keywords
-
Journal
Scientific Reports
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-03-27
DOI
10.1038/srep04483
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis
- (2013) Yaohui Wang et al. CURRENT MEDICAL RESEARCH AND OPINION
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- CancerDR: Cancer Drug Resistance Database
- (2013) Rahul Kumar et al. Scientific Reports
- Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets
- (2013) Naif Zaman et al. Cell Reports
- The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
- (2012) Kristine Kleivi Sahlberg et al. Molecular Oncology
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Cancer biomarkers: selecting the right drug for the right patient
- (2012) Gary J. Kelloff et al. NATURE REVIEWS DRUG DISCOVERY
- Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
- (2012) Stephanie J. Gros et al. PLoS One
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- Innovative biomarker development for personalized medicine in breast cancer care
- (2011) George C Zografos et al. Biomarkers in Medicine
- Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells
- (2011) Yong Zhao et al. CANCER LETTERS
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)
- (2010) Cristina Oliveras-Ferraros et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- FoxM1 Mediates Resistance to Herceptin and Paclitaxel
- (2010) Janai R. Carr et al. CANCER RESEARCH
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines
- (2010) N. Hevir et al. CHEMICO-BIOLOGICAL INTERACTIONS
- HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
- (2010) Merel Gijsen et al. PLOS BIOLOGY
- Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development
- (2009) J. Fasano et al. ANNALS OF ONCOLOGY
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- HSPB7 is a SC35 speckle resident small heat shock protein
- (2009) Michel J. Vos et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Jalview Version 2--a multiple sequence alignment editor and analysis workbench
- (2009) A. M. Waterhouse et al. BIOINFORMATICS
- MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
- (2009) Shawn P. Fessler et al. BREAST CANCER RESEARCH AND TREATMENT
- Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
- (2009) D. Faratian et al. CANCER RESEARCH
- Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
- (2009) G. Zhuang et al. CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
- (2009) M. Dokmanovic et al. MOLECULAR CANCER THERAPEUTICS
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- HER2/Neu Detection by Immunohistochemistry
- (2009) Hugo M. Lourenço et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
- (2008) Se Hun Kang et al. BMC CANCER
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Transforming Growth Factor Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab
- (2008) S. E. Wang et al. MOLECULAR AND CELLULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started